Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

PR Newswire

LAS VEGAS, Feb. 11, 2021

- Thrombocytopenia Treatment Market is expected to experience robust expansion due to the rise in patient pool and availability of products

LAS VEGAS, Feb. 11, 2021 /PRNewswire/ --DelveInsight's "Thrombocytopenia Market" report provides a thorough comprehension of the Thrombocytopenia,  historical and forecasted epidemiology, and the Thrombocytopenia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Thrombocytopenia market report also proffers an analysis of recent Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs. 

DelveInsight

Some of the vital points from the Thrombocytopenia Market Research Report

For additional information on Market Impact by Therapies, visit: Thrombocytopenia Therapeutics Market Analysis 

Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, sometimes, are not known. The main Thrombocytopenia symptoms include mild-to-severe bleeding. Bleeding can occur inside the body or underneath the skin, or from the skin's surface. As per DelveInsight's analysts, the total number of Thrombocytopenia cases in the 7MM was 1,653,934 in 2020. The Thrombocytopenia cases are expected to increase throughout the study period of 2018–2030 with a decent CAGR.

The Thrombocytopenia Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

Request sample report for more insights @ Thrombocytopenia Market Insight 

Thrombocytopenia Treatment Market 

Thrombocytopenia treatment depends on its cause and severity. The main goal of Thrombocytopenia treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment. 

One treatment approach is a direct treatment to the etiology of thrombocytopenia. Unfortunately, only in a minority of cases is the etiology of thrombocytopenia exact and the cause found. In a case of severe bleeding, if the thrombocytopenia etiology is not known but not thought to be immunologic, platelet transfusion can be used to proffer an immediate platelet increase. 

Patients with inherited thrombocytopenia have been treated with platelet transfusions. The option of allogeneic stem cell transplantation is reserved for inherited thrombocytopenia with a high risk of marrow failure or a rising risk of acute leukemia. 

Many Immune Thrombocytopenia cases (ITP) can be left untreated, and spontaneous remission in children is common. If therapy is required, the first-line treatment option is generally corticosteroids. The most effective second-line treatment option is splenectomy. Further, second-line treatment options with documented evidence of efficacy comprise various agents: azathioprine, cyclosporine, cyclophosphamide, danazol, dexamethasone, vinca alkaloids, mycophenolate mofetil, rituximab, and thrombopoietin-receptor agonists. 

The use of thrombopoietin-receptor agonists is an effective and safe second-line treatment strategy. Two thrombopoietin-receptor agonists were authorized to treat chronic ITP in adults by the US Food and Drug Administration (FDA) in 2008 and have been utilized extensively for chronic ITP treatment in relapsed and refractory patients. These were romiplostim, a thrombopoietin mimetic formed from peptides (peptibody), and eltrombopag (a small molecule, non-peptide).

The mainstay of Thrombotic Thrombocytopenic Purpura (TTP) treatment is plasmapheresis with plasma replacement. Other treatment modalities in non-responders to plasmapheresis include immune-suppression, not limited to high dose steroids and B-cell depleting agents (e.g., rituximab). 

Thrombocytopenia Emerging Therapies Along with Key Players 

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved soon. The major key players enumerated below can create a significant positive shift in Thrombocytopenia market size. 

And others.

Concluding thoughts on Thrombocytopenia Market Growth 

Thrombocytopenia Market Drivers 

Thrombocytopenia Market Barriers 

Scope of the Thrombocytopenia Market Insight 

Request for a Webex demo of the report @ Thrombocytopenia Market Size Analysis 

Table of Contents 

1

Key Insights on Thrombocytopenia

2

Executive Summary of Thrombocytopenia

3

Thrombocytopenia Market Overview at a Glance

4

Disease Background and Overview: Thrombocytopenia

5

Thrombocytopenia Patient Journey

6

Thrombocytopenia Epidemiology and Patient Population

6.1

United States Epidemiology

6.2

EU5 Countries Epidemiology

6.2.1

Germany

6.2.2

France

6.2.3

Italy

6.2.4

Spain

6.2.5

United Kingdom

6.3

Japan Epidemiology

7

Thrombocytopenia Treatment

8

Thrombocytopenia Unmet Needs

9

Thrombocytopenia Marketed Drugs

9.1

Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)

9.2

Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

9.3

Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)

9.4

Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.

9.5

Nplate (Romiplostim, AMG-531): Amgen

9.6

Promacta (eltrombopag): Novartis

9.7

Rituxan (rituximab): Zenyaku Kogyo

10

Thrombocytopenia Emerging Drugs

10.1

Key Cross Competition

10.2

Rozanolixizumab (UCB7665): UCB Biopharma

10.3

Rilzabrutinib (PRN-1008): Principia Biopharma

10.4

TAK-755 (BAX930/SHP655): Baxalta/Takeda

10.5

Efgartigimod (ARGX-113): Argenx

10.6

GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma

10.7

Narsoplimab (OMS721): Omeros Corporation

10.8

BT-595: Biotest

10.9

TAK-079: Millennium Pharmaceuticals/Takeda

10.10

Thrombosomes: Cellphire

10.11

M254 (Hypersialylated IgG): Momenta Pharmaceuticals

10.12

BIVV020: Sanofi

10.13

Interleukin 2: ILTOO Pharma

10.14

SKI-O-703: Genosco (Subsidiary of Oscotec)

11

7MM Thrombocytopenia Market Analysis

12

United States Thrombocytopenia Market Outlook

13

EU-5 Thrombocytopenia Market Outlook

13.1

Germany Market Size

13.2

France Market Size

13.3

Italy Market Size

13.4

Spain Market Size

13.5

United Kingdom Market Size

14

Japan Thrombocytopenia Market Outlook

15

Thrombocytopenia Market Drivers

16

Thrombocytopenia Market Barriers

17

SWOT Analysis

18

Reimbursement and Thrombocytopenia Market Access

19

Appendix

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

Browse detailed TOC with charts, figures, tables @ Thrombocytopenia Market Size Report  

View Related Reports  

DelveInsight's Thrombocytopenia - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Thrombocytopenia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Thrombocytopenia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Thrombocytopenia market.

Thrombocytopenia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Thrombocytopenia.

DelveInsight's Chemotherapy-induced thrombocytopenia (CIT) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Immune Thrombocytopenia (ITP) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight' s Idiopathic Thrombocytopenic Purpura - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

DelveInsight's Endocarditis disease Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

DelveInsight' s Community-Acquired Bacterial Pneumonia (CABP) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

Ambulatory Arrhythmia Monitoring Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Ambulatory Arrhythmia Monitoring Devices.

Neuroendoscopy Market Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of the Neuroendoscopy Market and the historical and forecasted epidemiology.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Contact Us:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Voltar noticias em Inglês